Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery

Cephalalgia

Volumn 31, Issue 2, 2011, Pages 181-189

  Chan, Kayi Y ^a   Baun, Michael ^b   De Vries, René ^a   Van Den Bogaerdt, Antoon J ^a   Dirven, Clemens M F ^a   Danser, Alexander H J ^a   Jansen Olesen, Inger ^b   Olesen, Jes ^b   Villalón, Carlos M ^c   Maassenvandenbrink, Antoinette ^a   Gupta, Saurabh ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c Farmacobiología ^*  (Mexico)

Author keywords

PAC1; PACAP38; VIP; VPAC1; VPAC2

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE 2; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; MESSENGER RNA; PG 97269; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CORONARY ARTERY; DRUG RECEPTOR BINDING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MENINGEAL ARTERY; MIGRAINE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; RECEPTOR BLOCKING; VASODILATATION;

ADULT; AGED; CORONARY VESSELS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MENINGEAL ARTERIES; MIDDLE AGED; MIGRAINE DISORDERS; PEPTIDE FRAGMENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; VASOACTIVE INTESTINAL PEPTIDE; VASODILATION; VASODILATOR AGENTS;

EID: 79751496802     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102410375624     Document Type: Article

References (35)

1. Arulmani U., MaassenVanDenBrink A., Villalón CM, and Saxena PR Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 2004 ; 500: 315-330. (Pubitemid 39304018)
2. Villalón CM and Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 2009 ; 124: 309-323.
3. Edvinsson L. and Goadsby PJ Neuropeptides in headache. Eur J Neurol 1998 ; 5: 329-341. (Pubitemid 28365275)
4. Birk S., Sitarz JT, Petersen KA, et al. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 2007 ; 140: 185-191. (Pubitemid 46418917)
5. Hansen JM, Sitarz J., Birk S., et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 2006 ; 26: 992-1003. (Pubitemid 44079724)
6. Rahmann A., Wienecke T., Hansen JM, Fahrenkrug J., Olesen J., and Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 2008 ; 28: 226-236. (Pubitemid 351172031)
7. Schytz HW, Birk S., Wienecke T., Kruuse C., Olesen J., and Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009 ; 132: 16-25.
8. Dickson L. and Finlayson K. VPAC and PAC receptors: From ligands to function. Pharmacol Ther 2009 ; 121: 294-316.
9. Vaudry D., Falluel-Morel A., Bourgault S., et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 2009 ; 61: 283-357.
10. Tajti J., Uddman R., and Edvinsson L. Neuropeptide localization in the "migraine generator" region of the human brainstem. Cephalalgia 2001 ; 21: 96-101. (Pubitemid 32575471)
11. Uddman R., Goadsby PJ, Jansen I., and Edvinsson L. PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. J Cereb Blood Flow Metab 1993 ; 13: 291-297. (Pubitemid 23067464)
12. Uddman R., Tajti J., Hou M., Sundler F., and Edvinsson L. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 2002 ; 22: 112-116. (Pubitemid 34494131)
13. Knutsson M. and Edvinsson L. Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport 2002 ; 13: 507-509. (Pubitemid 34293200)
14. Mulvany MJ and Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977 ; 41: 19-26. (Pubitemid 8132079)
15. Batenburg WW, van Esch JH, Garrelds IM, et al. Carvedilol-induced antagonism of angiotensin II: a matter of alpha1-adrenoceptor blockade. J Hypertens 2006 ; 24: 1355-1363. (Pubitemid 43948335)
16. MaassenVanDenBrink A., Reekers M., Bax WA, Ferrari MD, and Saxena PR Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998 ; 98: 25-30. (Pubitemid 28312075)
17. Gupta S., Mehrotra S., Villalón CM, et al. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur J Pharmacol 2006 ; 530: 107-116. (Pubitemid 43037131)
18. Arunlakshana O. and Schild HO Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 1959 ; 14: 48-58.
19. Goadsby PJ The vascular theory of migraine - a great story wrecked by the facts. Brain 2009 ; 132: 6-7.
20. Schoonman GG, van der Grond J., Kortmann C., van der Geest RJ, Terwindt GM, and Ferrari MD Migraine headache is not associated with cerebral or meningeal vasodilatation - a 3T magnetic resonance angiography study. Brain 2008 ; 131: 2192-2200.
21. Edvinsson L. CGRP-receptor antagonism in migraine treatment. Lancet 2008 ; 372: 2089-2090.
22. MaassenVanDenBrink A., Duncker DJ, and Saxena PR Migraine headache is not associated with cerebral or meningeal vasodilatation - a 3T magnetic resonance angiography study. Brain 2009 ; 132 (Pt. 6). e112.
23. Tietjen GE, Herial NA, White L., Utley C., Kosmyna JM, and Khuder SA Migraine and biomarkers of endothelial activation in young women. Stroke 2009 ; 40: 2977-2982.
24. Burstein R., Levy D., and Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol (Paris) 2005 ; 161: 658-660. (Pubitemid 40933999)
25. Saetrum Opgaard O., Gulbenkian S., and Edvinsson L. Innervation and effects of vasoactive substances in the coronary circulation. Eur Heart J 1997 ; 18: 1556-1568. (Pubitemid 27412411)
26. Dalsgaard T., Hannibal J., Fahrenkrug J., Larsen CR, and Ottesen B. VIP and PACAP display different vasodilatory effects in rabbit coronary and cerebral arteries. Regul Pept 2003 ; 110: 179-188. (Pubitemid 36165054)
27. Jansen-Olesen I., Gulbenkian S., Engel U., Cunha e Sa M., and Edvinsson L. Peptidergic and non-peptidergic innervation and vasomotor responses of human lenticulostriate and posterior cerebral arteries. Peptides 2004 ; 25: 2105-2114. (Pubitemid 39574451)
28. Baun M., Olesen J., and Jansen-Olesen I. Expression studies and pharmacological characterization of VIP and PACAP receptors in the cerebral circulation of the rat. Cephalalgia 2009 ; 29 (Suppl. 1). 133.
29. Boni LJ, Ploug KB, Olesen J., Jansen-Olesen I., and Gupta S. The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. Cephalalgia 2009 ; 29: 837-847.
30. Fahrenkrug J., Hannibal J., Tams J., and Georg B. Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab 2000 ; 20: 1205-1214. (Pubitemid 30636756)
31. Hernández M., Barahona MV, Recio P., et al. Neuronal and smooth muscle receptors involved in the PACAP-and VIP-induced relaxations of the pig urinary bladder neck. Br J Pharmacol 2006 ; 149: 100-109. (Pubitemid 44299073)
32. Edvinsson L., Chan KY, Eftekhari S., et al. Characterization of the CGRP receptor antagonist telcagepant in human isolated cerebral and meningeal arteries. Cephalalgia 2009 ; in press.
33. Gourlet P., Vandermeers A., Vandermeers-Piret MC, Rathe J., De Neef P., and Robberecht P. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. Eur J Pharmacol 1995 ; 287: 7-11.
34. Gourlet P., Vandermeers A., Van Rampelbergh J., et al. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors. Ann NY Acad Sci 1998 ; 865: 247252.
35. Akerman S. and Goadsby PJ VPAC1 and PAC1 receptor antagonists inhibit activation of the parasympathetic outflow to the cranial vasculature to prevent autonomic responses and neuronal firing in the trigeminocervical complex. Cephalalgia 2009 ; 29 (Suppl. 1). 130.